AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Actin, gamma-enteric smooth muscle

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P63267

UPID:

ACTH_HUMAN

Alternative names:

Alpha-actin-3; Gamma-2-actin; Smooth muscle gamma-actin

Alternative UPACC:

P63267; B2R7E7; B4E315; D6W5H8; E9PG30; P12718; Q504R1; Q6FI22

Background:

Actin, gamma-enteric smooth muscle, known as Alpha-actin-3, Gamma-2-actin, or Smooth muscle gamma-actin, plays a crucial role in cell motility. This highly conserved protein is ubiquitously expressed across eukaryotic cells, underscoring its fundamental role in cellular functions.

Therapeutic significance:

The protein is implicated in Visceral myopathy 1 and Megacystis-microcolon-intestinal hypoperistalsis syndrome 5, diseases affecting smooth muscle function in the gastrointestinal tract. Understanding the role of Actin, gamma-enteric smooth muscle could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.